Amgen, Abgenix win fast-track for experimental cancer therapy

The FDA has given its fast track designation to Amgen and Abgenix for panitumumab, an experimental fully human monoclonal antibody directed against the epidermal growth factor receptor, for patients with metastatic colorectal cancer who have failed standard chemotherapy treatment. News that the cancer drug was being put on a swift review process sent shares of both companies higher this morning.

- read this press release for more

Suggested Articles

Rachel Humphrey, M.D., who joined CytomX as chief medical officer after heading immuno-oncology at AstraZeneca and Eli Lilly, has made her exit.

Scientists have discovered a scorpion toxin could inspire treatments to block the inflammation that triggers chronic pain.

The phase 2 success keeps Hal Barron’s group on track to file for approval in multiple myeloma by the end of the year.